Bodenstedt Matthias 4
4 · MoonLake Immunotherapeutics · Filed Jun 18, 2026
Research Summary
AI-generated summary of this filing
MoonLake (MLTX) CFO Matthias Bodenstedt Sells Shares
What Happened
Matthias Bodenstedt, Chief Financial Officer of MoonLake Immunotherapeutics (MLTX), sold a total of 17,876 shares in open-market transactions on June 17–18, 2026, receiving aggregate proceeds of about $351,576. The larger sale on June 17 was 15,082 shares at a weighted average price of $19.68 ($296,814), and the June 18 sale was 2,794 shares at a weighted average price of $19.60 ($54,762). These were sales (not purchases).
Key Details
- Dates and prices:
- 2026-06-17: 15,082 shares sold, weighted average price $19.68; reported price range $19.50–$20.06 (F2).
- 2026-06-18: 2,794 shares sold, weighted average price $19.60; reported price range $19.505–$19.70 (F3).
- Total shares sold: 17,876; total proceeds ≈ $351,576.
- Footnotes:
- F1: Transactions executed under a Rule 10b5-1 trading plan adopted December 10, 2025 (pre‑arranged plan).
- F2/F3: Reported prices are weighted averages; the filer notes the SEC, the issuer, or a security holder can request a breakdown of shares sold at each separate price.
- Shares owned after transaction: Not specified in the summary information provided on this Form 4.
- Timeliness: Form filed June 18, 2026 for transactions on June 17–18, 2026 (filed within the typical Form 4 reporting window).
Context
The sales were executed under a pre-established 10b5-1 trading plan, which is commonly used to schedule trades in advance and can reduce the appearance that trades are based on nonpublic information. The filing shows routine insider sales; it does not provide evidence of the insider’s motivations.
Insider Transaction Report
- Sale
Class A ordinary shares, par value $0.0001 per share
[F1][F2]2026-06-17$19.68/sh−15,082$296,814→ 1,157,349 total - Sale
Class A ordinary shares, par value $0.0001 per share
[F1][F3]2026-06-18$19.60/sh−2,794$54,762→ 1,154,555 total
Footnotes (3)
- [F1]This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025.
- [F2]The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $19.50 to $20.06. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- [F3]The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $19.505 to $19.70. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.